Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan

Novartis will buy the Indiana-based biotech Endocyte and its experimental radiopharmaceutical drug for $2.1 billion, the Swiss pharma announced Thursday, furthering an expansion into nuclear medicine begun last year with the acquisition of Advanced Accelerator Applications.